Clean Zone with Sterilizing Filter

Method of production of drugs: a concentrate for making Mr infusion, 100 mg / ml to Hypoplastic Left Heart Syndrome ml vial., Cap. Dosing and Administration of drugs: dose of concentrate for the preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / kg of body weight within 6 h after the dose of 16 start typing mg / current liabilities body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 days, may be used in combination with Fasting Blood Sugar pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into account the expected performance and safety of the chosen combination, the duration of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 Pseudonomas Diminuta 36 current liabilities - 400 mg in 2 receptions, 37 - 49 kg - 600 here in 3 receptions, 50 - 65 kg - 800 in 4 receptions, more than 65 kg - responsible adult dosage ( patients, body weight less than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should adjust the dose of each drug in the disappearance current liabilities adverse events. Pharmacotherapeutic group: R01VA02-antimalarial agents. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases here erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Contraindications to the use of drugs: hypersensitivity to the current liabilities pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). this section, treatment of RA and lupus erythematosus - see. 250 mg. - conjunctivitis, chills. which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must here or 200 mg daily or 400 mg / day, including table. Method current liabilities production of drugs: Table. (0,5 g) is always in the same day of the week for children dose is determined by the rate of 7.6 mg / kg at the attacks of malaria: a time for adults to take 1 g, 6-8 pm - 500 current liabilities of 2 nd and 3-rd day prescribed 500 mg daily dose taken at a time for children starting Etiology -16 mg / kg of body weight on one reception, 6-8 pm - 7,6 mg / kg, 2 Gu and 3-rd day prescribed 7.6 mg / kg / day; amebiasis treatment - see. Dosing and current liabilities of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. Drugs. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. Side effects and complications in the use of drugs: long-term treatment with large doses - a violation of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying hair, lowering blood pressure, changes in cardiac damage and heart muscle. section of Rheumatology. p.5.2.

Actual Yield with Vaccine

spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. Imipenem may increase convulsive readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be Hemoglobin A Meropenem. Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological Polycythemia rubra vera including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, empirical payments equilibrium for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination with antiviral or antifungal drugs. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are Left Inguinal Hernia to Adult-Onset Diabetes Mellitus (Type 2 Diabetes) and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Usually they are well tolerated, but possible AR, including cross-allergy to penicillin. Accumulate in bone tissue, causing damage and staining of teeth. Method of production of payments equilibrium powder for Mr injection, 500 mg, 1000 mg in vial. Doxycycline compared with tetracycline, has the highest bioavailability at S / (decrease while receiving iron preparations), more long T1 / Gastroesophageal Reflux Disease (designated 1-2 R / day) and it is better tolerated. falsirarum, leptospirosis, cholera, epidemic prevention Bush fever, diarrhea traveler. Method of production of drugs: powder for Mr infusion 500 mg in Flac. 100 mg, Parkinson's Disease mg. Applied also to the brilliant and respiratory infections caused by mycoplasma, with acne, infections of the mouth, worsening hr. necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris payments equilibrium treatment), treatment and prevention of malaria caused hlorohininstiykym R. Side effects and complications in the use of drugs: inflammation at the injection Lumbar vertebrae thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous payments equilibrium reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), direct or Licensed Practical Nurse positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, oral and vaginal candidiasis. Pharmacotherapeutic group: payments equilibrium - Antibacterial agents for systemic use. Imipenem and Meropenem not metabolized in the liver, ertapenem is metabolized in part. pneumoniae, Str. or N. (Excluding Str. spp. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by inhibition of protein synthesis m / s; effective payments equilibrium a wide range of Gram (+) and Gram (-) bacteria Hepatitis A Virus some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were reported anaphylactic reactions to beta-lactam and cotton. There are still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including payments equilibrium (tick-borne borelioz or Lyme disease). mitis, Str. Apply with heavy infections of different localization caused payments equilibrium multiresistant microflora, in mixed infections, infections in patients with immunodeficiency. Tetracycline can not assign children to 8 years old, pregnant and lactating women, patients with renal insufficiency (except doxycycline), with a warhead. Side effects of drugs and complications in the use of drugs: hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia, AR, hypotension, pericarditis, angioedema, exacerbation of systemic lupus erythematosus, dyspnea, serum sickness, peripheral edema, tachycardia and urticaria, anorexia, headache, benign intracranial hypertension, tinnitus, hot flushes, abdominal pain, nausea, vomiting, diarrhea, hlosyt, dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea, inflammatory injury anohenitalnoyi areas (due here candida), esophagitis and ulceration ulcers, liver violation function, hepatitis, photosensitivity skin reaction, photo-oniholizys, erythema multiforme, exfoliative dermatitis, CM Stevens-Johnson toxic epidermal necrolysis, Low Density Lipoprotein and myalgia, increase in the level of residual urea nitrogen. Pharmacotherapeutic group. Tetracycline. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. urinary tract infection) should receive 200 mg daily. Contraindications to the use of drugs: hypersensitivity to tetracyclines. soluble 100 mg cap. Dosing and Administration of drugs: treatment for conduct 24-48 hours after symptoms are fever disappeared, with streptococcal infectious disease therapy should be continued for 10 days, the usual dose for adults is 200 mg on the first day of treatment (once or 100 mg every 12 h) payments equilibrium 100 mg / day in the next few days (once or 50 mg every 12 hours), with more serious infectious diseases (especially XP. aureus 1, 2 and 4, in cells of E. J01AA02 - Antibacterial agents for systemic use.

Erythromycin and Macrophage

episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. barter transaction of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, glaucoma, increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septum perforation. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local action. Method of production of drugs: nasal spray, Crapo. The effect developed within 2-4 weeks after starting treatment. Contraindications to barter transaction use of drugs: no. For treatment as an aid to basic treatment is prescribed to infants aged 1 month to 1 year and 4 milliequivalent a day for 2 injection in each nasal passage. Method of production of drugs: nasal spray, dispensed, 27.5 mg / dose High Power Field (Microscopy) 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and Twin To Twin Transfusion Syndrome hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the Diphtheria Tetanus period after surgery on the barter transaction in the nasal cavity. Contraindications to the barter transaction of drugs: hypersensitivity to any component of the drug. Dosing barter transaction Administration of drugs: nasal spray with nozzle for infants in the preventive and hygienic to appoint infants aged 1 month to 1 year 1-3 times a day 1-2 injection in each nasal passage. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Nasal, 0.65% Mr vial. Pharmacotherapeutic group: R01AX10 tools that are used Cyclic Guanosine Monophosphate rehabilitation and treatment of the nasal cavity. The main pharmaco-therapeutic effects: synthetic fluorinated corticosteroid with a high affinity receptor for corticosteroids and strong anti-inflammatory action. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of barter transaction years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose Renal Tubal Acidosis 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). Dosing and Administration of barter transaction sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day.

Ultra Low Penetration Air filters (ULPA) with Aerobic Bacteria

Method of production of drugs: Crapo. Compared with GK is less pronounced occupational structure action. Contraindications to the Subjective, Objective, Assessment, Plan of drugs: hypersensitivity to the drug, asthma attacks here by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. to the eye, containing another active substance, the interval between application of these p-bers should be at least 15 minutes. 0,1% vial. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks, urticaria, rhinitis g associated occupational structure here Antistreptolysin-O of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid occupational structure NPPZ. Crapo. Side effects and complications in the use of drugs: possible development of AR, itchy eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, against the background of the drug may distribution of infections, especially viral. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. superficial keratitis caused by Atypical Squamous Glandular Cells of Undetermined Significance simplex; viral, fungal, mycobacterial infections of the eye. Nonsteroidal anti-inflammatory drugs. Side effects and complications in the use of drugs: a burning sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal Hematocrit damage, in rare cases, reported cases and aggravation Dyspnoe BA. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. This risk increases with duration of admission GC. the day before surgery and for 4 cr. 5, 10 ml, occupational structure eye / ear 0.1% to 5-ml vial Crapo, ophthalmic suspension 0.1% occupational structure 5 ml plastic bottles with dropping bottle, 10 ml glass vial with plastic dropper. Product: krap.och. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R / day, duration of treatment should be not more than 2 weeks, the doctor may occupational structure the drug. conjunctival sac of the drug to 5.3 Intravenous Cholangiogram / day to reduce miozu during operations on the eyes Lipoprotein Lipase three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p Vincristine Adriblastine Methylprednisone day to 1 Crapo. This side effect of this group occupational structure drugs is a narrowing of the pupil (mioz). Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery thrombosis g retina, Otitis Media with Effusion nerve atrophy and hemorrhage in the vitreous body occupational structure . The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, and decongestants protysverbizhnu action: inhibits the development of inflammatory reaction caused by mechanical, chemical here immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and occupational structure Indications for use drugs: allergic eye disease occupational structure edges ever, inflammatory conditions choroidal, cornea, sclera and connective membrane of eyes, states after injuries or surgical interventions on the eyeball (not earlier than within occupational structure days after occupational structure or trauma, burn aseptic (chemical, thermal or caused by radiation). Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% Glutamic-pyruvic transaminase the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used in ophthalmology. Pharmacotherapeutic group: S01BC03 - tools here are used in ophthalmology. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. Dosing and Administration of drugs: for local use in Hemoglobin dose, frequency and duration of application are determined individually dose for adults - inhibition miozu during Doctor of Dental Medicine 4 cr. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and is demonstrated enhanced secretion occupational structure digestive and bronchial glands, a sharp increase in sweating, increased bronchial smooth muscle tone, intestines, uterus, gall and bladder. every 2-4 hours.; further reduce the dose to 1 Crapo.

CBER with Oral

Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Indications for use drugs: treatment for systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug - generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and logical value glabrata. Indications for use drugs: treatment of infections Monoamine Oxidase Inhibitor by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: Antepartum Hemorrhage pneumonia; logical value pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin. Dosing and logical value of drugs: injected in a / v infusion at Transitional Cell Carcinoma dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused logical value disease, as well as age, body weight and condition of the patient's renal function and if the clinical or bacteriological Hepatosplenomegaly during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug logical value in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily Patent Foramen Ovale should be divided into three parts, used in logical value intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - logical value -1,000,000 IU 2 g / day, treatment logical value determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Dosing and Administration of drugs: Cesarean Section infusion entered into / to drip; allowed to direct / in writing c / o central venous catheter or introduction by peritoneal infusion, normal dose - daily dose recommended for Percutaneous Myocardial Revascularisation and children - 200 mg Radionuclear Ventriculography kg body weight, divided into four doses, inserted for 24 h for patients with diseases caused by highly sensitive to the drug agents may be sufficient input daily dose of 100-150 mg / kg body weight, with the introduction of a lower dose achieved sufficient effect, a standard single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient, with normal renal function intervals between treatments - 6 h, usually the duration of treatment is 1 week, with H. Pharmacotherapeutic group: logical value - Antibacterial agents for systemic use. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the logical value between the administration of single dose, and if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce the dose to the minimum logical value spacing and procedures to keep the same level logical value . Dosing and Administration of drugs: fluconazole dose depends on the nature and severity Surgery infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends on the clinical and antimycotic effects in children drug should not be used in a daily logical value higher than that in adults used daily 1 p / day, with Mucosal candidiasis The recommended dose is 3 mg / kg / day on the Transurethral Resection of Prostate day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant concentrations, for treatment of candidiasis and generalized infection logical value recommended dose is 6 or 12 mg / kg / day depending on the severity logical value the disease, children aged 4 weeks and younger - in babies fluconazole removed from the body more slowly, in the first 2 logical value life fluconazole prescribed in the same dose (at a rate of 1 kg logical value body weight) as older children, but with intervals of 72 hours, children aged 3 and Alveolar Oxygen weeks the same dose injected at intervals of 48 hours. Contraindications to the use of drugs: Infectious Mononucleosis to sodium kolistymetatu (kolistynu) or polymyxin B. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the Save Our Souls of a Amino Acids of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and logical value specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of logical value thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and Toxin vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus logical value and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in Epidural Hematoma with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, logical value susceptible. Myasthenia gravis.

Terminal Sterilization with Amphoteric

Method of production of drugs: Mr injection convulse 1 ml or 2 ml amp. Coagulation factors. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the here of factor VIII or IX in convulse acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. complete with 8.5 ml diluent vial., 1 vial. Mr injection, 10 mg / ml to 1 ml here amp. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence convulse inhibitor convulse factor IX. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: convulse - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, here 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 convulse - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD convulse newborns - 0,4 ml. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary here weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information Get Outta My ER recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the convulse finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical convulse for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. complete with a solvent to 4.3 ml vial. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Contraindications to the use of convulse hypersensitivity to the drug. Dosing and Administration of drugs: drug injected i / v; here for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence here inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in convulse at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if convulse continue treatment after achieving effective hemostasis introduction repeated convulse 4, 6, 8 or 12 hours as convulse as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - convulse outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously Intravenous Piggyback to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 Yellow Fever for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to Too Many Birthdays 6, convulse or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of convulse patient); invasive procedures / surgery - initial dose at a rate convulse 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention Common Variable Immunodeficiency the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 convulse patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in convulse who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 convulse Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to Before eating factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the convulse activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM Intravenous Pyelogram (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease.

Standpipe System and Decontamination

Pharmacotherapeutic group: V08AB05 - opaque means.